Advertisement
Abstract| Volume 21, SUPPLEMENT 3, S92-S93, November 2020

A subgroup analysis from the IMvigor130 study in patients with upper tract vs. lower tract locally advanced or metastatic urothelial carcinoma treated with atezolizumab plus platinum-based chemotherapy

Open AccessDOI:https://doi.org/10.1016/S2666-1683(20)36166-8
A subgroup analysis from the IMvigor130 study in patients with upper tract vs. lower tract locally advanced or metastatic urothelial carcinoma treated with atezolizumab plus platinum-based chemotherapy
Previous ArticleMolecular subtypes of fully resected clear cell renal cell carcinoma are prognostic for risk of relapse and may impact adjuvant treatment
Next ArticleHybrid ICG-99mTc-nanocolloid, on the road towards becoming the new standard for sentinel node biopsy in penile cancer?
      This paper is only available as a PDF. To read, Please Download here.

      Article info

      Identification

      DOI: https://doi.org/10.1016/S2666-1683(20)36166-8

      Copyright

      © 2020 Elsevier B.V. Published by Elsevier Inc.

      User license

      Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
      How you can reuse Information Icon
      Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)

      Permitted

      For non-commercial purposes:

      • Read, print & download
      • Redistribute or republish the final article
      • Text & data mine
      • Translate the article (private use only, not for distribution)
      • Reuse portions or extracts from the article in other works

      Not Permitted

      • Sell or re-use for commercial purposes
      • Distribute translations or adaptations of the article

      Elsevier's open access license policy

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX